長江生命科技(00775.HK)擬共同投資PHARUS, INC.
格隆匯7月25日丨長江生命科技(00775.HK)發佈公吿,2022年7月25日,公司全資附屬公司長江生命科技投資者、長和投資者(長和全資附屬公司)、Quark及Pharus(Quark全資附屬公司)訂立認購協議,據此,長江生命科技投資者及長和投資者各自已認購,而Pharus已向各投資者發行若干A2系列優先股,故於緊隨該發行後,長江生命科技投資者及長和投資者各自持有Pharus已發行股本總數約18.33%。
Pharus擬應專注於癌症早期檢測分子診斷的研究、開發及商業化。交易完成前,Quark已根據由Quark與Pharus訂立的資產轉讓及許可協議向Pharus轉讓或允許Pharus使用若干資產(包括用於Pharus將開展的業務的專利權、專有技術及實物資產)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.